If you’re shopping for a wallet and one comes complete with $100 worth of cash inside, and is priced at $60, would you think there is value to this purchase? A situation similar to this has evolved in many biotech stocks. Their balance sheet cash and cash equivalents exceed their market value. Whether the broader market recognizes the value in these companies and pushes prices up, or large-pharma, currently flush with cash, swoops in to own more than their purchase price, remains to be seen. But, the value many of these firms offer is more than just their R&D, patents, or product pipeline. It is also measurable assets in excess of where the market currently values the company. Read More >>